Menzel Garry E's Form 4 filing
TCR2 Therapeutics Inc. (TCRR) · filed Dec 5, 2022
- Accession no.
- 0001209191-22-059881
- Filed
- Dec 5, 2022
- Trade date
- Dec 1-2, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $11.7K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Menzel Garry ECIK 0001556064 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Common Stock | MOption exerciseAcquired | +221,058 | – | – | 221,058 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −8,408 | $1.39 | −$11,687.12 | 212,650 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Common Stock | MOption exerciseAcquired | +158,795 | $0.00 | $0 | 3,241 | Direct | |
| Dec 1, 2022 | Common Stock | MOption exerciseAcquired | +40,881 | $0.00 | $0 | 15,120 | Direct | |
| Dec 1, 2022 | Common Stock | MOption exerciseAcquired | +21,382 | $0.00 | $0 | 23,165 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.